Overview

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The hypothesis is that application of Mupirocin to the nose before and after coronary artery bypass grafting surgery will reduce the incidence of surgical site infections.
Phase:
Phase 3
Details
Lead Sponsor:
Horizon Health Network
Treatments:
Mupirocin